Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 29, 2018 08:30 ET | Source: EyeGate Pharmaceuticals, Inc.

EyeGate Pharmaceuticals Announces Participation at the H.C. Wainwright 20th Annual Global Investment Conference

WALTHAM, Mass., Aug. 29, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for...
August 20, 2018 08:30 ET | Source: EyeGate Pharmaceuticals, Inc.

EyeGate Announces Enrollment of First Patient in PRK Pilot Study

WALTHAM, Mass., Aug. 20, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for...
August 07, 2018 08:30 ET | Source: EyeGate Pharmaceuticals, Inc.

EyeGate Pharmaceuticals Announces New Board Member, Peter Greenleaf

WALTHAM, Mass., Aug. 07, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary...
August 03, 2018 08:30 ET | Source: EyeGate Pharmaceuticals, Inc.

EyeGate Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Business Update

WALTHAM, Mass., Aug. 03, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage, specialty pharmaceutical company with two proprietary...
July 24, 2018 08:30 ET | Source: EyeGate Pharmaceuticals, Inc.

EyeGate Announces FDA Approval of Two IDE Submissions for Ocular Bandage Gel

FDA Grants Approval for Studies for Patients that have undergone Photorefractive Keratectomy and for Patients with Punctate Epitheliopathies WALTHAM, Mass., July 24, 2018 (GLOBE NEWSWIRE) --...
June 22, 2018 08:30 ET | Source: EyeGate Pharmaceuticals, Inc.

EyeGate Addresses Final FDA Action Item with Submission of IDE Amendment for Ocular Bandage Gel

Responses to the last of four outstanding action items submitted; Potential to start clinical study in the Third Quarter of 2018 WALTHAM, Mass., June 22, 2018 (GLOBE NEWSWIRE) -- EyeGate...
May 30, 2018 08:30 ET | Source: EyeGate Pharmaceuticals, Inc.

EyeGate Files Supplement to Investigational Device Exemption to Commence Study in Punctate Epitheliopathy using the EyeGate Ocular Bandage Gel

WALTHAM, Mass., May 30, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary...
May 22, 2018 08:30 ET | Source: EyeGate Pharmaceuticals, Inc.

EyeGate Addresses Majority of FDA’s Action Items with Submission of Investigational Device Exemption Amendment for Ocular Bandage Gel

Responses to three of the four outstanding action items submitted; Response to Fourth action item Expected in the Second Quarter of 2018 with Potential to start clinical study in the Third Quarter of...
May 16, 2018 16:30 ET | Source: EyeGate Pharmaceuticals, Inc.

EyeGate Pharmaceuticals Announces New Board Member, Steven Boyd

WALTHAM, Mass., May 16, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary...
May 11, 2018 08:30 ET | Source: EyeGate Pharmaceuticals, Inc.

EyeGate Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update

WALTHAM, Mass., May 11, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right